AI · 19 Nov 2026 · 01:26 CET
Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted

Publisher preview · OZZZER analysis pending editorial review.
PUBLISHER ARTICLE PREVIEW
From the original article
Harbour BioMed announced on November 18, 2026 that China’s National Medical Products Administration had accepted the investigational new drug (IND) application for LET003, its first drug candidate developed using the Hu-mAtrIx AI platform. The monoclonal antibody is intended to treat overweight or obesity by blocking the activin receptors ACVR2A and ACVR2B.
The milestone is acceptance of an application to enter clinical development, not a reported clinical result. The efficacy findings in the announcement come from preclinical studies, so they do not establish weight loss or body-composition changes in patients. Harbour BioMed’s therapeutics pipeline lists LET003 as a global obesity program alongside LET001 in weight management.
Dr. Bob Zhang, president of Harbour BioMed’s Metabolic Disease Franchise, said obesity treatment is moving “beyond weight reduction alone toward improving body composition and achieving more sustainable health outcomes.” The company’s concern is the lean-mass loss that can accompany substantial weight reduction with GLP-1-based therapies.
Source
Unite.AI · 19 Nov 2026 · 01:26 CET
Open the original at Unite.AI ↗